Início › Câncer de Mama › Geórgia

Ensaios clínicos de Câncer de Mama em Geórgia

53 estudos para Câncer de Mama estão buscando participantes em locais em Geórgia.

Cidades em Geórgia

Texto oficial do estudo (Inglês)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Northeast Georgia Medical Center Braselton, Braselton
Atlanta VA Medical Center, Decatur
Northeast Georgia Medical Center-Gainesville, Gainesville
e mais 4

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades de 40 a 75 · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Winship Cancer Institute, Emory University, Atlanta

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06369285

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

Emory Proton Therapy Center, Atlanta

RecrutandoFase 3

Idades 19 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05856773

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Emory University Hospital, Atlanta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 28 de set. de 2026 · NCT05646862

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

City of Hope Cancer Center - Atlanta ( Site 0102), Newnan

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Emory University Winship Cancer Institute, Atlanta
Liberty County Cancer Care, Hinesville
Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
e mais 2

RecrutandoFase 3

Idades 60 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06377852

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Marietta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
Central Georgia Cancer Care, Macon
City of Hope National Medical Center, Atlanta Cancer Center, Newnan
e mais 2

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Emory University School of Medicine - Winship Cancer Institute, Atlanta

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07114601

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Winship Cancer Institute, Atlanta

RecrutandoFase 2

Idades 18 e acima · Mulheres · Atualizado em 22 de set. de 2026 · NCT07287098

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University Cancer & Blood Center, LLC, Athens
Winship Cancer Institute of Emory University, Atlanta

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT06827236

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

University Blood & Cancer Center, LLC, Athens
Winship Cancer Institute, Atlanta
Northside Hospital, Atlanta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 15 de set. de 2026 · NCT06492616

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Georgia Cancer Center at Augusta University, Augusta

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06293898

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Emory University (Data Collection Only), Atlanta

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 9 de set. de 2026 · NCT05570253

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

University Cancer & Blood Center, LLC, Athens
Summit Cancer Care, Savannah

RecrutandoFase 1

Idades de 18 a 55 · Mulheres · Atualizado em 9 de set. de 2026 · NCT07310420

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Marietta

RecrutandoFase 3

Idades de 18 a 130 · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Winship Cancer Institute of Emory University, Atlanta

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 8 de set. de 2026 · NCT07100106

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Emory University, Atlanta

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 4 de set. de 2026 · NCT06400472

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Atlanta Cancer Care - Northside Hospital, Atlanta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06982521

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Emory University, Atlanta

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT05846789

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Northwest Georgia Oncology Centers PC - Marietta, Marietta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 3 de set. de 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Phoebe Putney Memorial Hospital, Albany
University Cancer and Blood Center LLC, Athens
Grady Health System, Atlanta
e mais 16

RecrutandoFase 3

Idades de 18 a 60 · Mulheres · Atualizado em 2 de set. de 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Winship Cancer Institute of Emory University, Atlanta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06072612

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Emory University - Winship Cancer Institute, Atlanta

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 27 de ago. de 2026 · NCT06582017

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Augusta University, Augusta

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 21 de ago. de 2026 · NCT06764940

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Emory University Hospital/Winship Cancer Institute, Atlanta

RecrutandoVoluntários saudáveis bem-vindos

Idades 18 e acima · Todos os sexos · Atualizado em 14 de ago. de 2026 · NCT07764796

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Winship Cancer Institute at Emory University, Atlanta

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT06263543

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Emory University, Atlanta

RecrutandoFase 1

Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT05304962

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Northside Hospital, Atlanta

RecrutandoFase 2/3

Idades 18 e acima · Todos os sexos · Atualizado em 10 de ago. de 2026 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

City of Hope - Cancer Center Atlanta, Newnan

RecrutandoFase 3

Idades de 18 a 100 · Todos os sexos · Atualizado em 6 de ago. de 2026 · NCT05232916

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Augusta University Georgia Cancer Center, Augusta

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

Grady Health System, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
e mais 3

RecrutandoFase 3

Idades de 18 a 50 · Todos os sexos · Atualizado em 4 de ago. de 2026 · NCT06748222

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Emory University, Atlanta

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT07288359

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 7 de jul. de 2026 · NCT05768139

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

RecrutandoFase 1/2

Idades 18 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

GSK Investigational Site, Atlanta

RecrutandoFase 2

Idades 18 e acima · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT04641247

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Emory University School of Medicine, Atlanta

RecrutandoFase 3

Idades 18 e acima · Todos os sexos · Atualizado em 22 de jun. de 2026 · NCT05696626

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

Emory University Hospital/Winship Cancer Institute, Atlanta

RecrutandoVoluntários saudáveis bem-vindos

Idades 25 e acima · Mulheres · Atualizado em 26 de mai. de 2026 · NCT06760507

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Emory University/Winship Cancer Institute, Atlanta

RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos

Idades 18 e acima · Mulheres · Atualizado em 7 de mai. de 2026 · NCT05877859

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.